NCT00444223

Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants.

Detailed description

OBJECTIVES: * Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer (NSCLC) and in healthy participants. * Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron emission tomography in patients with stage III or IV NSCLC. OUTLINE: This is a pilot study. Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body dynamic scans comprising positron emission tomography. Blood is collected during and after imaging to measure radioactivity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
PROCEDURE	fluorine F 18 FEQA + positron emission tomography

Timeline

• Start date: 2004-05-04
• Primary completion: 2008-05-15
• Completion: 2008-05-15
• First posted: 2007-03-07
• Last updated: 2020-08-05

Locations

1 site across 1 country: United States